GLP-1 Use Increased Significantly Among Pediatric Patients With T2D in Past 5 Years | ADA 2025
From 2019 to 2024, GLP-1 prescriptions among pediatric patients with type 2 diabetes increased from 12.3% to 60.9%.
Glucagon Prescribing Not in Full Alignment With ADA Guidelines | ADA 2025
The most frequent barriers to access to glucagon include cost, patient health literacy, and insurance coverage.
Obesity Medication Use Remains Low Among Children | ADA 2025
Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.
Ambulatory Care Pharmacists Help Decrease A1c Levels in Primary Care Program | ADA 2025
The initiative focuses on managing medications for high-risk diabetes patients through a collaborative drug therapy agreement.
Racial Disparities Persist in CGM Use, HbA1c | ADA 2025
Researchers presented an abstract describing current racial disparities in CGM access and wear time to better inform quality improvement efforts.
CDC Report Finds No Connection Between Thimerosal and Autism
Thimerosal is a mercury-containing compound that has been widely used as a preservative in some biological and drug products since the 1930s.
Procedure Shows Promise for Sustained Weight Loss After GLP-1 Therapy
Revita is a procedure that modifies duodenal dysfunction and restores metabolic health, according to Fractyl Health.
How Pharmacy Technician Burnout Impacts Patient Care
Taylor Watterson, PharmD, PhD, discusses how distress experienced by pharmacy technicians can impact the overall safety and quality of pharmacy operations.
GLP-1s Serving as the Intersection of Cost, Utilization
Pharmaceutical Strategies Group experts joined Drug Topics to discuss the role GLP-1s play in drug benefit design.
FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis
This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.
$0 Copay Program Effectively Improved Glycemic Control | ADA 2025
Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.
Obesity-Related Mortality Rose After COVID-19 Pandemic | ADA 2025
In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.
Pharmacist Outreach Can Help Reduce Hypoglycemia Risk | ADA 2025
Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.
Telemedicine With GLP-1 Behavior Program Shows Significant Declines in Weight, Blood Pressure | ADA 2025
In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.
Equipping Pharmacists for Evidence-Based Abortion Medication Access
Nicole Cieri-Hutcherson, PharmD, BCPS, MSCP, FCCP, discusses how pharmacists can support patient counseling and education around medication abortion.
Q&A: PBM Unbundling, New Pricing Models Create More Transparency
Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss how the role of PBMs in plan design is evolving.
Younger Adults Disproportionately Not Treated for Cardiometabolic Risk Factors | ADA 2025
When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.
Flexible Dosing Medications to Help Your Pharmacy Thrive
At the Total Pharmacy Solutions Summit Summer 2025 event, Stephanie Zimmerman, Tom Napolitano, and Luke Gunderson discussed the benefits of Real Value RX.
Pharmacists Play Key Role in Navigating Vaccine Misinformation and Disinformation
Kevin Cleveland, PharmD, discusses how pharmacists are uniquely positioned to provide immediate, direct interactions with patients, making them vital in addressing vaccine misinformation.
CGM Usage Improves Glycemic, Psychosocial Outcomes for Type 1 Diabetes | ADA 2025
Investigators assessed continuous glucose monitoring with behavioral intervention for patients with type 1 diabetes.
Pharmacist Outreach Reduces Therapeutic Inertia in T2D | ADA 2025
Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.
Expanding Revenue Streams in Independent Pharmacy: Strategies for Today and the Future
Tara Pfund, PharmD, chief strategy officer with the Cascadia Pharmacy Group, discusses a variety of ways community pharmacists can expand services and support clinical reimbursement.
Pharmacist-Led Diabetes Coaching Improved Glycemic Control, Reduced Expenses | ADA 2025
Abstract researchers explored whether or not a pharmacist could serve as the lead of a diabetes coaching program, aiming to reduce medical expenditures and A1C levels for at-risk patients.
Turning Reconciliation into a Revenue Growth Engine
Heidi Polek, RPh, EMBA, discusses how pharmacies must adopt strategic approaches to maintain financial health and continue providing patient care.
Unlocking Pharmacy Value: A Guide to Payer Program Engagement
Emily Endres, BSPS, and Todd Sega, PharmD, MBA, discuss pressures that pharmacies are currently facing, including reimbursements, competition, and patient needs.
Q&A: Supporting Pharmacy Technicians Through Daily Recognition
Taylor Watterson, PharmD, PhD, discusses several different ways pharmacy technician contributions can be better recognized and appreciated.
Pharmacists Play Key Role in Expanding Access to Medication Abortion
Nicole Cieri-Hutcherson, PharmD, BCPS, MSCP, FCCP, discusses how pharmacist involvement in medication abortion can improve reproductive health care access.
Bridging Gaps, Building Connections: NCPDP’s New Vision for the Future of Pharmacy
John Hill, MBAHCM, and Pooja Babbrah, MBA, from the National Council for Prescription Drug Programs, discuss their organization’s strategic plan for advancing the pharmacy profession.
Conference Coverage Recap: American Pharmacists Association Annual Meeting and Exposition 2025
Check out our coverage from the American Pharmacists Association Annual Meeting and Exposition 2025!
How Drug Benefit Design Trends Are Expected to Impact Pharmacists
Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss the 2025 Trends in Drug Benefit Design Report and how it will impact pharmacists.